INTRODUCTION
Autoimmune hepatitis (AIH) is a progressive liver disease, occurring more frequently in females, which, if left untreated, leads to liver cirrhosis and hepatic failure [1] . Current therapies are based on long-term immunosuppression, which induce remission in a majority of patients; however, the risk of subsequent relapses is high. Adherence to the therapy is one of the crucial factors for achieving clinical success [2] .
Recent studies have demonstrated that patients with AIH suffer from a substantially diminished health-related quality of life [3] [4] [5] . In particular, depression has emerged as an under-estimated factor affecting the well-being of patients with AIH [6] . Unfortunately, depression is rarely assessed in everyday clinical practice. The Patient Health Questionnaire-9 (PHQ-9) and the Hospital Anxiety and Depression Scale (HADS) are simple screening tools, which have been successfully applied in AIH and indicated patients for further evaluation.
They do not, however, permit a precise assessment of the condition. Indeed, the final diagnosis of depression requires the appraisal of depression etiology, duration of symptoms, effect on daily activities, psychiatric history, and other factors that are not considered in the screening tools.
Given the above, we performed an extended psychiatric assessment which involved a detailed psychiatric evaluation, a battery of screening tests, and a structured interview (M.I.N.I.), focusing on patients with AIH who previously presented the highest scores in the depression screening test in our center.
MATERIALS AND METHODS
We prospectively included adult patients with AIH from our previous study [5] who had screened positively for moderately severe depression (>15 points on the PHQ-9 test).
According to Levis et al. [7] , this cut-off allows exclusion of major depression in 96% of patients. None of the included patients had signs of decompensated liver cirrhosis, hepatic encephalopathy, malignancies, previously diagnosed psychiatric diseases, or complained about side-effects of the AIH drugs. The study flow-chart is presented in Figure 1 . GAD-7, stemming from Primary Care Evaluation of Mental Disorders screening tool (PRIME-MD), is a self-administered screening test for core anxiety symptoms, primarily designed as a measure to screen for Generalized Anxiety Disorder, but also having sufficiently good operating characteristics for three other anxiety disorders: panic disorder, social anxiety disorder, and post-traumatic stress disorder [9] . The severity of anxiety is assessed by assigning 0, 1, 2, or 3 to the response categories "not at all", "several days", "more than half of the days", or "nearly every day", respectively, with a total score ranging from 0 to 21. The recommended cut-off point for further evaluation is a score of 10 or greater [9] .
The Mini-International Neuropsychiatric Interview (M.I.N.I.) M.I.N.I. is a structured psychiatric interview developed by Sheehan et al. [10] , allowing psychiatric diagnosis according to DSM-IV and ICD-10 psychiatric criteria, with good accuracy and reliability.
Alcohol Use Disorders Identification Test (AUDIT)
The AUDIT screening tool was used to exclude alcohol use disorders overlapping with depressive symptoms, anxiety, and liver disfunction [11] . Although patients with AIH are not commonly diagnosed with alcohol abuse or dependency, some of them are not committed to absolute abstinence after AIH diagnosis, which may shape the course of the disease and influence psychiatric symptoms, and a differential diagnosis should be documented. AUDIT 
RESULTS
Fourteen patients comprising 10% of the total number of 140 patients included into our previous study [5] had results suggesting moderately severe depressive symptoms in the screening tests. Four patients were excluded from further analysis: one had developed a decompensation of his liver function, the second was diagnosed with the hepatocellular carcinoma (HCC), and the two other patients were transplanted before the psychiatric assessment. The clinical data and results from the psychiatric evaluation are presented in the Supplementary materials (Table S1 ). None of the patients had a flare of AIH. The detailed psychiatric assessment consultations revealed a positive diagnosis of depression (present, past, or recurrent) in six patients (60%), as well as anxiety-or stress-related disorders in two patients (20%). Finally, six patients (60%) were recommended antidepressive agents (selective serotonin or serotonin and norepinephrine reuptake inhibitors) and were assigned a psychiatric follow-up. It is worth noting that nine patients had never sought psychiatric assistance before. Of interest, two patients who had undergone liver transplantation and were excluded from the cohort had no signs of depression in the follow-up but had been diagnosed with adjustment disorders (ICD-10: F43.2).
DISCUSSION
To the best of our knowledge, this is the first study, which estimates the prevalence of depression in AIH using full psychiatric check-up. We performed a thorough psychiatric assessment of patients who screened positively for moderately severe depression in a simple and commonly used questionnaire, the PHQ-9. This assessment showed that six out of ten patients had depression, which required medical therapy. Two of them were diagnosed with an anxiety-or stress-related disorder(s) as concomitant comorbidities. These results are in line with a recently published meta-analysis, which showed that a higher cut-off of the PHQ-9 (e.g., >15 points) could correctly rule out patients with major depression, but could also result in a false positive in 39% of the positively-screened patients [7] . The detailed psychiatric interview results confirmed the mentioned false positive rate using a higher cut-off of the PHQ-9, in the AIH setting. A lower specificity of the PHQ-9 was described in younger populations (7) , which corresponds well with our cohort of patients and may have affected the final results.
These findings suggest that the current available screening methods might not be adequate for estimating the real extent of depression and other psychiatric disorders in the setting of AIH. They could also explain the discrepancy in the results of positive screening for depression in published cohorts, which range from 5.5% to 29%, depending on the cohort [6] .
Overall, the herein-presented results further underscore the fact that presumed depression, detected with basic screening modalities, requires special attention in patients with AIH. It should be followed by thorough evaluation since therapeutic intervention may be required in the majority of the identified subjects. This is of particular importance for younger patients, as depression affects not only their well-being, but also their adherence to treatment.
The latter may detrimentally impact the outcome of therapy [2] . To accomplish this task, a close co-operation between hepatologists and psychiatrists is needed; importantly, dedicated screening tools must be developed and validated in the near future.
